Seeking Alpha

UBS says the recent weakness in Celgene (CELG -0.6%) presents a buying opportunity. The firm...

UBS says the recent weakness in Celgene (CELG -0.6%) presents a buying opportunity. The firm believes the pullback following the company's disappointing Q1 results is due to transient issues, and the company is still on track for Q2. The firm maintains its buy rating on the shares.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)